References
- Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348–354.
- Drayson MT, Tang LX, Drew R, Mead GP, Carr-Smith HD, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with non secretory multiple myeloma. Blood 2001; 97: 2900–2902.
- Lachman HI, Gallimore JR, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating immunoglobulin free light chains following chemother-apy. Br J Haematol 2003; 122: 78–84.
- Dingli D, Kyle RA, Rajkumar SV et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979–1983.
- Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–817.
- Kyrtsonis MC, Vassilakopoulos TP, Kafasi N. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240–243.
- Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK, Harris NL. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO classification of tumours — pathology and genetics of tumours of haemoatopoietic and lymphoid tissue. Lyon: IARC Press, 2001: 144–151.
- Michaux L. Plasma cell leukemia (PCL). Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: http://AtlasGeneticsOncology.org/Anomalies/PlasmCel.html (accessedOctober 1997).
- Mclaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 1982; 60: 851–855.